07:28 AM EDT, 09/22/2025 (MT Newswires) -- Pfizer ( PFE ) said Monday it has entered into a definitive agreement to acquire Metsera ( MTSR ) for $47.50 per share in cash, valuing the company at about $4.9 billion.

The acquisition will add differentiated oral and injectable incretin, non-incretin and combination therapy candidates to its pipeline.

The agreement, unanimously approved by the boards of both companies, also includes a contingent value right of up to $22.50 per share tied to three milestones: $5 per share upon the start of a phase 3 trial of Metsera's ( MTSR ) MET-097i+MET-233i combination; $7 per share upon US Food and Drug Administration approval of MET-097i monotherapy, and $10.50 per share upon FDA approval of the MET-097i+MET-233i combination.

The transaction is expected to close in Q4, pending regulatory and shareholder approvals and other customary conditions.